BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lockart I, Hajarizadeh B, Buckley N, Davison S, Prakoso E, Levy MT, George J, Dore GJ, Danta M. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol 2021. [PMID: 34520088 DOI: 10.1111/jgh.15687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Huo TI, Ho SY, Liao JI. Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role? J Gastroenterol Hepatol 2021. [PMID: 34654059 DOI: 10.1111/jgh.15707] [Reference Citation Analysis]
2 Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199 [DOI: 10.4254/wjh.v14.i6.1190] [Reference Citation Analysis]